Call for European Based Pharmaceutical Research Partner on Project to Develop COVID-19 Remote Monitoring System
We are urgently seeking a European-based pharmaceutical partner to collaborate on a project to develop a remote monitoring system to detect early markers of COVID-19.
In response to the IMI Call 21 we have assembled a preliminary consortium of partners with specific resources and expertise that can be applied in the development and validation of a system that repurposes a CE-marked device for the remote detection of COVID-19, potentially facilitating earlier disease detection and AI-driven triage decisions related to screening and hospitalization.
In this project, we will evaluate the use of the Ava Bracelet*, which uses sensors to measure breathing rate, pulse rate, skin temperature, heart rate variability, and skin perfusion for the purpose of early detection and monitoring of COVID-19 in populations at high risk of exposure. A prospective, observational study will follow 20,000 individuals from the general population and 10,000 high-risk individuals wearing the device and responding to patient self-report parameters via a purpose-designed app. Based on this data, an algorithm will indicate which individuals likely require further testing and/or hospitalization. To confirm accuracy in the algorithm, the cohort will be tested for COVID-19 antibodies—this will be compared to tests from a control population of 10,000 individuals using a self-report application only. Thus, this project will deliver a large set of information on COVID-19 antibodies that can be used to develop additional diagnostics and therapeutics in addition to validating a remote monitoring system.
We are looking for a pharmaceutical partner that is a member of the European Federation of Pharmaceutical Industries (EFPIA) association and can participate in the Innovative Medicines Initiative (IMI) program. If you are interest in participating, please let us know as soon as possible.
Why might you be interested:
- You would be involved in the a very large cohort study (20,000 to 30,000 device users) in NL and Lichtenstein
- You would work together with world renown Public Health and Infectious Disease Specialists (University of Utrecht, NL), Big Data & Machine Learning Experts (University College London) and manufacture of a wrist wearable device that continuously monitors temperature, heart rate and breathing rate (Ava AG)
- You would be part of a team who has combined forces to understand if we can better target testing, thus reducing Health Care System burden with the potential to reduce cross infection of First Responders and people in testing centers with the hope to reduce the spread of the disease, optimize medical response and reduce the economic burden of the pandemic.
- The EFPIA partner would ideally complement the team with a COVID-19 test and/or a repurposed therapy for COVID-19 but other working on adjacencies are highly welcome
- If the EFPIA partner is working on a new therapy this would mean immediate access to the data of the exposed but non symptomatic and exposed symptomatic participants and the possibility to test the treatment in the study.
- The data stream is expected to follow users throughout their clinical course, many before exposure. This set of data (data from up to 30,000 people) is of extreme value to anyone working in this area.
Prof. Dr Rick Grobbee, University of Utrecht & Dr. Maureen Cronin, Ava AG
*The Ava Bracelet is currently CE-marked according to MDD 93/42/EC for the purpose of measuring and displaying physiological parameters to facilitate conception and to provide general information on health and wellness to users. The device is listed with US FDA.
The Ava Bracelet is not approved for COVID-19 monitoring. This product is intended to support data collection and research during the COVID-19 pandemic but is not intended to diagnose, treat, cure, or prevent COVID-19.